

BOLSA DE PÓS-DOCTORAMENTO (M/F)

Referência: FP7-HEALTH-2013-INNOVATION-1 - NMTrypI

Título do Projecto: “New Medicines for Trypanosomatidic Infections”

Código interno: PR301504

Está aberto concurso para recrutamento de um(a) bolseiro(a) de Pós-Doutoramento para colaborar no projecto acima referido, financiado pelo “HEALTH.2013.2.3.4-2: Drug development for neglected parasitic diseases. FP7-HEALTH-2013-INNOVATION-1.”, através do Programa “Collaborative project - Small or medium-scale focused research project”.

A bolsa, em regime de exclusividade, terá a duração de 3 meses, renováveis, com início previsto a 1 de janeiro de 2016.

O valor mensal da bolsa será de € 1.495,00

Pago por transferência bancária (preferencialmente).

Programa de trabalho: The infectious diseases burden imposed by the parasites of Trypanosomatidae family represents a huge problem on people's lives in countries where these diseases are endemic. Problems associated with existing drugs include inefficient delivery, insufficient efficacy, excessive toxicity and increasing resistance. New drugs are urgently needed now and in the foreseeable future. The New Medicine for Trypanosomatid Infections (NMTrypI) consortium uses a highly interdisciplinary approach to optimize pteridine, benzothiazole and miltefosine derivatives, as well as natural products against Trypanosomatids. The lead compounds target mechanisms that are associated with protozoa virulence and pathogenicity. The major objectives of this 3-year project are: i) development of drug leads which may be used in combination with a known or an investigational drug, by using a common drug discovery platform established by experts in their respective fields, ii) development of pharmacodynamic biomarkers enabling the proteomic profiling of compound efficacy and early identification of drug resistance. NMTrypI addresses sleeping sickness, leishmaniasis, and Chagas disease. The partners are SMEs (5) and academics (8) in Europe and in disease-endemic countries (Italy, Greece, Portugal, Sudan, and South Korea). The new platform enables high throughput screening of compound libraries, lead development, testing in relevant animal models, as well as toxicology and safety testing. NMTrypI will translate drug leads into drug candidacy through 6 scientific work packages (WPs1-6) supported by two transversal WPs dedicated to project dissemination and management. The major strength of the consortium lies in the complementary partners' expertise and the integrated platform that will provide:

- at least 1-2 innovative, less toxic and safer drug candidates for Trypanosomatid infections compared to existing ones,
- early phase biomarkers for efficacy prediction (overall improved efficacy and safety)

Perfil pretendido:

Doutoramento em Ciências Farmacêuticas e afins, com experiência e total autonomia em sistema de quantificação de novos fármacos, realização de nanoformulações e estudos de farmacocinética e farmacodinâmica assim como em testes de segurança. Dá-se preferência a candidatos com



**EUROPEAN
COMMISSION**

**FP7 Specific Programme
IDEAS**



experiência na área. Exige-se domínio da língua Inglesa, falada e escrita e bom relacionamento inter-pessoal num contexto de uma equipa de investigação multidisciplinar.

O prazo para recepção de candidaturas decorre de 09 ao 23 de Dezembro de 2015.

As propostas deverão incluir uma carta de motivação, CV e 2 cartas de recomendação e ser submetidas no site do IBMC:

<http://www.ibmc.up.pt/gestaocandidaturas/index.php?codigo=PR301504>

A contratação será regida pelo estipulado na legislação em vigor, nomeadamente o “Estatuto do Bolseiro de Investigação Científica, aprovado pela Lei nº 40/2004, de 18 de agosto, alterado e republicado pelo Decreto-Lei nº 202/2012, de 27 de agosto.”, e o Regulamento de Bolsas de Investigação Científica do IBMC (www.ibmc.up.pt/fellowships.php).

